<DOC>
	<DOCNO>NCT02919904</DOCNO>
	<brief_summary>The feasibility use Apnea Risk Evaluating System ( ARESTM ) device take longitudinal measure sleep parameter asymptomatic men prostate cancer initiate androgen deprivation therapy ( ADT ) evaluate . Study participant complete serial questionnaire relate sleep quality , hot flash , quality life .</brief_summary>
	<brief_title>Feasibility Study Assessment Sleep Quality Men With Prostate Cancer Starting ADT</brief_title>
	<detailed_description>The primary purpose study examine feasibility use ARESTM device measure sleep parameter prostate cancer patient begin ADT . Although evidence link ADT poor quality sleep , research assess impact ADT sleep parameter . We choose ARESTM device study device comprehensively measure sleep parameter . Furthermore , unlike polysomnography , ARESTM device easy use measurement do participant ' home , without require adapt new sleep location ( e.g. , sleep lab ) . ARESTM wireless device wear forehead sleep record physiological parameter . In addition , feasibility obtain serial questionnaire patient assess . In pilot study , study investigator attempt make preliminary correlation sleep quality ( measure ARESTM ) subjective sleep quality , morphometric measure , urinary symptom , hot flash . Data collect study help determine acceptability compliance use ARESTM device patient population .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Newly diagnose prostate cancer start hormone therapy without concomitant radiation therapy least 6 month , 2 . Biochemical relapse prostate cancer without metastatic symptom ( i.e . rise Prostatespecific antigen ( PSA ) definitive therapy evidence metastatic disease ) * . 3 . Serum testosterone hypogonadal range , castrate level . 4 . About start ADT Luteinizing HormoneReleasing Hormone ( LHRH ) analogue least 6 month . 5 . Fluent English ( able read , write , speak English ) . 6 . Provide write informed consent . 7 . Patients sleep apnea depend CPAP ( continuous positive airway pressure ) machine sleep may join study . Note : For participant hormone therapy radiation , sleep parameter measure participant start radiation . 1 . Receiving antiandrogen monotherapy . 2 . Previous history sleep disorder ( e.g. , treated obstructive sleep apnea ( wear CPAP machine ) , narcolepsy , parasomnia , circadian rhythm abnormality ) . 3 . Use routine prescription counter sleep medication ( e.g. , melatonin , zolpidem , suvorexant , eszopiclone , ramelteon , benzodiazepine , antihistamine ) . 4 . Active medical problem interfere sleep ( e.g . congestive heart failure ) . 5 . Active medical problem interfere ARESTM reading use device : deafness , blindness , severe arthritis , dementia , atrial fibrillation , tic tremor head . 6 . Use supplemental oxygen night . 7 . Sensitivity skin scalp and/or open wound forehead scalp . 8 . Allergic reaction extend exposure synthetic fabric ( e.g . polyester , rayon ) . 9 . Upper respiratory infection congestion . 10 . Inability sleep least 5 hour per night total 8 hour two night . 11 . Inability sleep head recline ( less 60 degree angle ) . 12 . Head circumference le 21 inch great 25 inch . 13 . Any reason would prevent participant complete study protocol medical reason would preclude take part .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>sleep</keyword>
	<keyword>androgen deprivation therapy</keyword>
</DOC>